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Abstract
BACKGROUND:: There is a growing interest in the possible role of inflammatory biomarkers, such as interleukins, 
chemokines, growth factors, and acute-phase proteins, in cardiovascular risk-stratification.
AIM: The aim of the study was to determine a possible correlation between the subjects’ cardiovascular risk profile 
and various inflammatory markers and to assess the sole use of IL-6 in CVD risk prediction.
MATERIALS AND METHODS: Seventy-five healthy subjects participated. EUROSCORE, lipid, glycemic, and 
inflammatory markers were analyzed. Сhi-square test, t-test, one-way ANOVA, Mann–Whitney, and Kruskal–Wallis 
tests were used. Significance was determined at <0.05.
RESULTS: A multivariate analysis revealed 12 markers to be independently associated with CVD risk – LDL-C, TG, 
ApoB, HbA1c, hsCRP, IL-6, and IL-1A as markers of higher, and HDL-C, IL-4, Il-10, VEGF, and EGF as markers of 
lower CVD risk. IL-6 levels > 1 pg/ml were positively correlated with female gender, age > 55 years, EUROSCORE 
≥ 3, risk age, SBP, hsCRP > 2 mg/L, and IL-2 (p = 0.025, p = 0.013, p = 0.025, p = 0.011, p = 0.026, p = 0.046, and 
p = 0.018). Except for total CVD risk and risk age, the same variables were identified to be independently associated 
with IL-6.
CONCLUSION: Inflammatory biomarkers, especially hsCRP and IL-6, have a statistically significant, added 
predictive power in cardiovascular risk stratification.
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Introduction
Cardiovascular disease (CVD) remains a 
leading cause of morbidity and mortality, despite 
improvements in outcomes. Although age-adjusted 
coronary artery disease mortality has declined since the 
1980s, inequalities between countries persist and many 
risk factors, particularly obesity and diabetes mellitus 
(DM), have been increasing substantially [1].
Apart from the conventional major 
cardiovascular risk factors included in the currently 
used risk charts, there are other risk factors that 
could be relevant for assessing total CVD risk [2]. 
The previous has led to a vast investigation of 
CVD risk-modifiers, such as N-terminal fragment of 
prohormone B-type natriuretic peptide levels, von 
Willebrand factor antigen levels, fibrinogen levels, 
chronic kidney disease, leukocyte count, C-reactive 
protein (CRP) levels, homocysteine levels, uric acid 
levels, coronary artery calcium scores, carotid intima-
media thickness, peripheral arterial disease, and 
pulse wave velocity [3]. The nontraditional risk factors 
have resulted in varying degrees of improvement in 
discrimination and reclassification of risk, including 
no improvement [4].
Advances in vascular biology have established 
the interaction of the innate immune system and 
atherosclerosis, with emerging clinical studies linking 
chronic inflammation to future CV events [5]. Several 
biomarkers have been addressed to improve the 
identification of at-risk asymptomatic patients regarding 
the central role of inflammation in atherosclerosis 
initiation and progression [6].
The MRFIT (Multiple Risk Factor Intervention 
Trial) was one of the first prospective epidemiology 
studies to show a strong relationship between levels 
of high sensitivity CRP (hsCRP) and mortality from 
coronary heart disease in high-risk middle-aged 
men, as well as an association between increasing 
hsCRP levels and subsequent myocardial infarction 
and/or stroke rate in apparently healthy men [7]. The 
WHS (Women’s Health Study) showed hsCRP as 
a stronger predictor of CV events compared to low-
density lipoprotein cholesterol (LDL-C) in over 27 000 
apparently healthy women [8].
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The Emerging Risk Factor Collaboration 
(ERFC), while reviewing a possible association among 
hsCRP levels, CV risk factors, and vascular risk in 160 
309 individuals, found a similar magnitude-increased 
risk of higher hsCRP levels regarding coronary heart 
disease (RR: 1.68; 95% CI: 1.59–1.78), ischemic stroke 
(RR: 1.46; 95% CI: 1.32–1.61), and death from vascular 
causes (RR: 1.82; 95% CI: 1.66–2.00), all risk ratios 
similar to those seen for hyperlipidemia [9].
Despite the vast clinical studies addressing 
the role of CRP in CVD settings, the Jupiter 
(Justification for the Use of Statins in Prevention: 
An Intervention Trial Evaluating Rosuvastatin) trial 
is said to be the first to postulate hsCRP’s potential 
role in CVD prevention. Randomizing 17,802 middle-
aged to elderly, low to intermediate-risk patients with 
LDL-C <130 mg/dl and hsCRP >2 mg/l to rosuvastatin 
20 mg versus placebo, the trial reported a robust 
44% RRR (95% CI: 31% to 54%; p < 0.00001) in the 
primary endpoint of myocardial infarction, stroke, 
revascularization, hospitalization for unstable angina, 
or death; with 50% and 37% reductions in LDL-C and 
hsCRP levels in the rosuvastatin arm, respectively. 
Showing lowest CV events incidence in subjects 
achieving both low LDL-C and low hsCRP levels, the 
Jupiter study findings are used as evidence-based 
justification regarding the use of hsCRP as a screening 
tool for CVD risk stratification and as a marker in the 
treatment management process [10], [11].
While hsCRP is a clinically proven risk 
assessment tool, the biomarker itself is unlikely 
to provide an effective target for intervention. The 
previous has led to an increased interest in the 
inflammatory background of CVD as a whole [12]. The 
disturbance of the oxidative/anti-oxidative homeostasis 
in CVD perpetuates an inflammatory response in the 
subendothelial space, activating various immune cells 
to secrete pro-inflammatory molecules such as tumor 
necrosis factor-α (TNF-α) and interleukin-1 (IL-1). 
These promote secretion of monocyte chemoattractant 
protein-1 (MCP-1), which leads to monocyte recruitment 
and macrophage activation [13]. The process of 
atherosclerosis itself leads to the secretion of additional 
cytokines such as IL-10 and IL-6 and increases 
hepatic CRP synthesis, resulting in phagocytosis in 
the atherosclerotic plaque [14]. In addition, MCP-1 is 
thought to be one of the major regulators of vascular 
endothelial growth factor (VEGF) and epidermal growth 
factor (EGF), both cytoprotective and proangiogenic 
growth factors [15].
Upstream movement in the inflammatory 
cascade from CRP to IL-6–IL-1 has recently provided 
novel therapeutic opportunities for atheroprotection. 
Preliminary data from a single-dose study of tocilizumab 
(a humanized anti-IL-6 receptor antibody) in non-ST 
elevation myocardial infarction showed a reduction 
in the area under the CRP curve (ClinicalTrial.
gov NCT01491074) [16]. CANTOS (Canakinumab 
Anti-inflammatory Thrombosis Outcomes Study), with 
a population of more than 10,000 patients, is a study 
set out to test whether blocking the pro-inflammatory 
cytokine interleukin-1ß (IL-1ß) with canakinumab (a fully 
human monoclonal anti-IL-1β antibody), in comparison 
to placebo, reduces the rate of recurrent myocardial 
infarction, stroke, and cardiovascular death among 
patients who remain at high risk due to persistent 
CRP elevation (≥2 mg/l). Canakinumab directly inhibits 
the IL-1β–IL-6 to CRP axis, with no effect on LDL-C; 
thus, CANTOS will be the first large scale test of the 
inflammation hypothesis of atherothrombosis [17].
Although cytokine-targeted therapy with 
biological agents is slowly taking the focus regarding 
the anti-inflammatory CVD hypothesis, statins, the 
golden standard for cholesterol-lowering in patients 
at risk of/with CVD, have numerous anti-inflammatory 
and immunomodulatory pleiotropic properties yet to be 
determined and translated into the clinical practice.
The results that will be presented in the 
following paper are part of a research project evaluating 
the traditional versus pleiotropic actions of rosuvastatin 
in apparently healthy subjects at medium-to-high CVD 
risk.
The aim of the study was to determine a possible 
correlation between the subjects’ cardiovascular risk 
profile and various inflammatory markers; to assess 
whether IL-6 can be a better inflammatory marker than 
hsCRP in CVD risk prediction.
Materials and Methods
Study design, subjects, and protocol
This is a cross-sectional cohort study of 
subjects with moderate to high CV risk without known 
cardiovascular disease. Seventy-five adult ambulatory 
patients (aged 50.5 ± 12, 1 year, 41 women, 34 men) 
from the University Clinic of Cardiology in Skopje 
were included in the study. The study protocol 
was approved by the Clinical Studies and Ethics 
Committee of UKIM-Faculty of Medicine, Skopje. 
Every subject received verbal and written information 
and gave written consent before the start of the study. 
The study analyzed demographic indicators, family 
history, traditional CVD risk factors (smoking, arterial 
hypertension [HTA], hyper/dyslipidemia [HLP], 
diabetes mellitus [DM], and obesity), calculated 
EUROSCORE risk, SCORE risk age, SCORE relative 
risk, using a predefined algorithm: www.heartscore.
org, and determined lipoprotein profile indicators 
(total cholesterol [Chol], low-density lipoprotein 
cholesterol [LDL-C], high-density lipoprotein 
cholesterol [HDL-C], triglycerides [TG], apolipoprotein 
A1 [ApoA1], apolipoprotein B [ApoB], and lipoprotein 
B - Clinical Sciences Cardiology
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[a] Lp(a)), glycemic profile indicators (fasting 
glucose, glycosylated hemoglobin A1c [HbA1c]), and 
inflammatory profile indicators (interleukins [IL-1A, 
IL-1B, IL-2, IL-4, IL-6, IL-8 and IL-10]), cytokines (tumor 
necrosis factor-α [TNF-α] and interferon-γ [IFN-γ]), 
chemokines (monocyte chemoattractant protein-1 
[MCP-1]), growth factors (epidermal growth factor 
[EGF] and vascular endothelial growth factor [VEGF]), 
and acute phase proteins (C-reactive protein [CRP]).
Data were obtained from the patients’ medical 
history, physical examination, and blood samples taken 
on the day of the clinical visit. A comparative analysis 
was performed based on the presence/absence of: 
HLP, DM, and a hsCRP value >2 mg/L.
Methods
4.0 mL venous blood in two EDTA/K3 vacuum 
tubes was taken from each patient and immediately 
transported (by a chain maintaining a 4°C temperature of 
the samples) and analyzed after sampling. Biochemical 
parameters were determined at the University Clinic 
of Clinical Biochemistry, Skopje, and the inflammatory 
markers were determined at the Institute of Pathology, 
UKIM-Faculty of Medicine, Skopje, with the methods 
described in Appendix 1.
Statistical analysis
Continuous variables are expressed as mean 
value ± SD and categorical variables are expressed 
as absolute numbers. Chi-square test, t-test, and one-
way ANOVA were used for the variables that follow the 
normal distribution, while nonparametric tests, such as 
Mann–Whitney and Kruskal–Wallis tests, were used to 
analyze the continuous variables that deviated from the 
normal distribution. Correlations and ROC curves were 
computed, and uni- and multivariate logistic regression 
analysis was made. Results were considered statistically 
significant when p ≤ 0.05. Data were analyzed using the 
IBM SPSS 19.0 statistical software.
Results
General characteristics of the study 
population
We included 75 patients with moderate to high 
CV risk in the study. General characteristics of the study 
population in a comparative manner (as a function of 
the presence of HLP, diabetes, or hsCRP >2 mg/L) are 
shown in Table 1.
The total estimated EUROSCORE (%) in the 
study population is 3.5, which places it in the group of 
individuals with a moderate-to-high 10-year risk of fatal 
CVD. The calculated relative risk is 2,7, or nearly a 3-fold 
(Contd...)
Variable No (%) WITH HLP 
(%)
WITHOUT 
HLP
Sig WITH 
DM
WITHOUT 
DM
Sig hsCRP>2 hsCRP<2 Sig
Gender
Female
Male
75 (100%)
41 (54.7%)
34 (45.3%)
64 (85.3%)
36 (48%)
28 (37.3%)
11(14.7%)
5(6.7%)
6(8%)
ns 15(20%)
10(13.3%)
5(6.7%)
60(80%)
31(41.3%)
29(38.7%)
Ns
ORf 1.4
(CI0.7-3.1)
38(50.7%)
26(34.7%)
12(16.0%)
37(49.3%)
15(20.0%)
22(29.3%)
0.014
ORf 1.9
(CI 1.1-3.2)
Age
Female
Male
50.5 ± 12.1
52.5 ± 10.8
48.1 ± 13.3
51.1 ± 11.2 47.2 ± 16.7 ns 59.7±9.7 48.2±11.6 0.001 51.4±12.4 49.5±11.9 ns
Smoking 14 (18. .7) 13 (20.3%) 1(9.1%) ns 5(33.3%) * 9(15.0%) * ns 5(13.2%) 9(24.3%) Ns
Family history 10 (13.3) 9 (14.1%) 1(9.1%) ns 0 10 (16.7%) * ns 5(13.2%) 5(13.5%) Ns
HTA 54 (72) 47(73.4%) 7(63.6%) ns 14(93.3%) * 40(66.7%) * 0.034; OR1.3
(CI 1.1-1.5)
33(86.8%) 21(56.8%) 0.004; OR 1.9 
(CI1.3-2.9)
DM 15 (20) 14(21.9%) 1(9.1%) ns 8(21.1%) 7(18.9%) ns
Pre-diabetes 35 (46.7) 28(43.8%) 7(63.6%) ns / 35(58.3%) 0.000 18(47.4%) 17(45.9%) ns
HLP 14(93.3%) * 50 (83.3%) * ns 33(86.8%) 31(83.8%) ns
BH (cm) 169.0 ± 9.7 169 ± 9.3 169.2 ± 12.7 ns 168.7 ± 10.5 169.7 ± 9.7 ns 167.3 ± 10.3 170.8 ± 8.9 ns
BW (kg) 79.1 ± 14.0 79.3 ± 14.5 77.8 ± 12.1 ns 78.1 ± 15.4 79.2 ± 13.9 ns 79.4 ± 12.7 78.7 ± 15.6 ns
BMI 27.6 ± 4.1 27.7 ± 4.2 27.2 ± 3.3 ns 27.6 ± 5.1 27.6 ± 3.9 ns 28.3 ± 3.5 26.9 ± 4.6 ns
SBP mmHg 134.8±17.7 135 ± 19 140 ± 18 ns 142.7 ± 20.9 132.8 ± 16.4 0.050 135.8 ± 18.0 133.8 ± 17.5 ns
EUROSCORE risk profile
EUROSCORE (%) 3.5±4.3 3.8 ± 4.5 1.4 ± 1.3 0.078 6.7 ± 6.0 2.7 ± 3.3 0.001 3.8 ± 3.8 4.1 ± 5.5 ns
Low risk
Intermediate risk
High risk
Very high risk
12 (16%)
43 (57.3%)
13 (17.3%)
7 (9.3%)
9(14.1%)
35(54.7%)
13(20.3%)
7(10.9%)
3(27.3%)
8(72.7%)
0
0
ns
0.073** 
0
7(46.7%)
4(26.7%)
4(26.7%)
12(20%)
36(40%)
9(15%)
3(5%)
0.016
6(15.8%)
20(52.6%)
8(21.1%)
4(10.5%)
6(16.2%)
23(62.2%)
5(13.5%)
3(8.1%)
ns
Risk age 56.2±7.9 56.5 ± 7.7 54.7 ± 9.1 ns 60.7 ± 4.6 55.1 ± 8.2 0.014 55.9 ± 9.8 55.3 ± 8.1 ns
Relative risk 2.7±1.8 3.0 ±  2.0 2.0 ±  0.8 0.006 3.9 ± 2.9 2.5 ± 1.4 0.008 2.9 ± 1.5 3.1 ± 2.7 ns
No of pts. with risk age 
>biological age
47 (62.7%) 40(62.5%) 7(63.6%) ns 6(40%) 41(68.3%) 0.043**
ORnonDM2.5
(CI 1.0-6.3)
22(57.9%) 25(67.6%) ns
LP profile
Chol >5mmol/L 65 (86.7%) 54(91.1%) 11(14.7%) 0.000 14(93.3%) 50(83.3%) ns 21(46.7%) 20(44.4%) ns
Chol (mmol/L) 6.3±1.4 6.7 ± 1.1 4.2 ± 0.3 0.000 6.5 ± 1.4 6.3 ± 1.4 ns 6.8 ± 1.3 6.3 ± 1.5 ns
LDL-C (mmol/L) 4.0±1.4 4.3 ± 1.2 2.2 ± 0.4 0.001 4.2 ± 1.4 3.9 ± 1.4 ns 4.3 ± 1.4 3.8 ± 1.5 ns
HDL-C (mmol/L) 1.4±0.3 1.4 ± 0.4 1.2 ± 0.2 ns 1.4 ± 0.4 1.4 ± 0.3 ns 1.5 ± 0.4 1.3 ± 0.3 0.066
TG (mmol/L) 2.3±2.0 2.4 ± 2.1 1.5 ± 0.9 ns 3.3 ± 3.9 1.9 ± 1.1 0.018 2.0 ± 1.1 2.8 ± 3.2 ns
ApoA1 (g/L) 1.6±0.3 1.7 ± 0.3 1.5 ± 0.2 ns 1.6 ± 0.3 1.6 ± 0.3 ns 1.7 ± 0.4 1.6 ± 0.3 ns
ApoB (g/L) 1.4±0.4 1.5 ± 0.3 1.0 ± 0.4 0.000 1.4 ± 0.4 1.4 ± 0.4 ns 1.5 ± 0.4 1.4 ± 0.4 ns
Lp(a) (mg/tdl) 42.1±58.8 39.7 ± 55.5 55.8 ± 77.3 ns 27.5 ± 20.3 45.7 ± 64.6 ns 40.7 ± 43.4 39.8 ± 50.9 ns
Table 1: General characteristics of the study population
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increased CVD risk compared to an equivalent population 
with normal risk factor values. The risk age of the study 
population (a person of the same sex and risk level, but 
with ideal risk factor values) is ~56 years, 6 years higher 
than the actual average age. More than half of the study 
population (62.7%) has a risk age > biological age.
The presence of HLP shows a significant 
correlation with a relative risk (3.0 ± 2.0 with HLP, 
compared to 2.0 ± 0.8 without HLP, p = 0.006).
The presence of DM is significantly correlated 
with HTA (14 [93.3%] vs. 40 [66.7%], p = 0.034; OR 1.3 
[CI 1.1–1.5]), total estimated EUROSCORE (%) (6.7 ± 
6.0 vs. 2.7 ± 3.3, p = 0.001), risk age (60.7 ± 4.6 vs. 
55.1 ± 8.2, p = 0.014), and relative risk (3.9 ± 2.9 vs. 2.5 
± 1.4, p = 0.008), with/without DM, respectively. DM is 
positively correlated with MCP-1 levels (130.2 ± 102.8 
vs. 73.9 ± 63.6 in the group without DM, p = 0.050).
hsCRP levels > 2 mg/L are significantly 
correlated with female gender (26 (34.7%) vs. 15 (20.0%) 
in the group with hsCRP levels < 2 mg/L, p = 0.014; ORf 
1,9 (CI 1.1–3.2), and HTA [33(86.8%) vs. 21(56.8%) in the 
group with hsCRP levels < 2 mg/L, p = 0.004; OR 1.9 (CI 
1.3–2.9)]. hsCRP levels > 2 mg/L are positively correlated 
with IL-6 levels (1.9 ± 2.2 vs. 1.0 ± 0.6, p = 0.017).
Inflammatory biomarkers
At the present moment, there are no defined 
ranges of “normal values” of inflammatory biomarkers. 
Table 2 shows cytokine concentration (mean and range) 
measured in our study cohort and ranges measured by 
different investigators in the healthy adult population, with 
the intention simply to give you an overview of the current 
situation of reported ranges of inflammatory biomarkers.
We performed a gender analysis of 
inflammatory biomarkers. Compared to males, females 
have higher levels of hsCRP and IL-6 (4.2 ± 4.7 vs. 1.9 ± 
1.5 and 1.9 ± 2.1 vs. 0.9 ± 0.5, respectively), statistically 
significant with both parametric and nonparametric 
tests (p = 0.008/p = 0.002 and p = 0.010/p = 0.003, 
respectively) (Table 3).
We analyzed possible interrelations between 
the inflammatory biomarkers, to identify significant 
correlations. We revealed numerous significant 
Table 2: Cytokine concentration ranges in the “healthy adult population” reported by different authors and in our study group
Cytokine (pg/ml) Mean1 (range) Mean2 (range) Mean3 (range) Study group
IL2 1.1 (1.1–9.2) 14 (9.4-15.9) 6.46 (0.03-90) 1.8±1.0 (0.0-5.55)
IL-4 2.7 (1.9–3.8) 0.10 (0.01-3.0) 2.0±0.7 (0.0-3.99)
IL-6 4.6 (1.1–10.8) 0.73 (0.02-9.0) 1.4±1.6 (0.12-11.29)
IL-8 3.9 (1.0–8.2) 29.3 (24.4-35.9) 7.21 (0.08-116) 4.5±5.6 (0.41-29.45)
IL-10 4.3 (2.4–6.6) 12.6 (8.5-16.7) 0.13 (0.10-2.0) 0.6±0.5 (0.0-3.66)
IL-1A 1.4 (LLOD)* 0.12 (0.40-1.40) 0.3±0.2 (0.0-0.87)
IL-1B 2.6 (0.8–3.9) 3.2 (LLOD) 0.01 (0.02-0.70) 1.6±1.0 (0.0-5.35)
IFN-γ 77.1 (48.4–127.6) 13.43 (7-124) 0.3±0.8 (0.0-6.07)
TNF-α 35.3 (14.2–61.7) 5.92 (0.10-98.0) 2.0 ± 1.8 (0.38-11.63)
VEGF 11 (4.6–20.3) 61.6 (32-118.9) 0.43 (0.01-9.0) 35.3 ± 31.8 (5.05-147.76)
EGF 46.7 ± 63.1 (0.02-302.16)
MCP-1 16 (10.6-24.0) 41.5 (20.1-78.9) 18.24 (2.0-48.0) 83.4 ± 73.9 (1.26-314.66)
*LLOD-lower limit of detection. 1 Heidi Kokkonen. Ingegerd So¨derstro¨m.1 Joacim Rocklo¨v. Go¨ran Hallmans. Kristina Lejon. Solbritt Rantapa¨a¨ Dahlqvist. Up-Regulation of Cytokines and Chemokines Predates the Onset 
of Rheumatoid Arthritis. ARTHRITIS and RHEUMATISM. American College of Rheumatology; Vol. 62. No. 2. February 2010. pp 383–391. 2Giulio Kleiner. Annalisa Marcuzzi. Valentina Zanin. Lorenzo Monasta. and Giorgio 
Zauli. Cytokine levels in the serum of healthy subjects. Hindawi Publishing Corporation. Mediators of inflammation; Volume 2013. Article ID 434010. 6 pages. 3Normal Physiological Levels of Human Cytokines Using Bio-Plex 
Pro™ Cytokine Assays. Philip Chapman. Candice Reyes. and Vinita Gupta Bio-Rad Laboratories. Inc.. Hercules. CA 94547 USA (2010)
Variable No (%) WITH HLP 
(%)
WITHOUT 
HLP
Sig WITH 
DM
WITHOUT 
DM
Sig hsCRP>2 hsCRP<2 Sig
Glycemic profile
Glycemia 6.4±4.9 6.6 ± 5.2 5.7 ± 2.1 ns** 8.9 ± 4.5 5.8 ± 4.8 0.025 5.8 ± 1.8 7.1 ± 6.7 ns
Glycated hemoglobin 
(HbA1c-%)
6.0±1.0 6.0 ± 1.0 5.7 ± 0.4 ns** 7.2 ± 1.5 5.7 ± 0.3 0.000 5.9 ± 0.6 6.1 ± 1.2 ns
HbA1c categorical
<5.6 mmol/L
5.6-6.5 mmol/L
>6.5 mmol/L
24 (32%)
41 (54.7%)
10 (13.3%)
21(32.8%)
34(53.1%)
9(14.1%)
3(27.3)
7(63.6%)
1(9.1%)
ns**
0
5(33.3%)
10(66.7%)
24(40%)
36(60%)
0
0.000
12(31.6%)
21(55.3%)
5(13.2%)
12(32.4%)
20(54.1%)
5(13.5%)
ns
Uric acid 314.6 ± 73.6 313.2 ± 74.6 318.1 ± 72.4 ns** 305.9 ± 71.7 316.7 ± 74.4 ns 317.6 ± 68.9 311.4 ± 78.8
Biomarkers of inflammation/proliferation
hsCRP (mg/L) 3.2±3.8 3.2 ± 3.8 3.0 ± 3.9 ns** 3.4 ± 3.4 3.1 ± 3.9 ns** 5.2 ± 4.5 1.1 ± 0.3 0.000
NO of pts. with hsCRP 
>2 mg/L
38(50.7%) 33(51.6%) 5(45.5%) ns** 8(53.3%) 30(50%) ns** 38(50.7%) 37(49.3%) ns**
hsCRP category
hsCRP ≤1 mg/L
hsCRP >1≤3 mg/L
hsCRP >3 mg/L
21(28%)
30(40%)
24(32%)
18(28.1%)
25(39.1%)
21(32.8%)
4(36.4%)
4(36.4%)
3(27.3%)
ns**
4(26.7%)
5(33.3%)
6(40%)
18(30%)
24(40%)
18(30%)
ns**
22(29.5)
29(38.7%)
24(32%)
ns**
IL-2 1.8±1.0 1.8 ± 0.9 2.0 ± 1.3 ns** 1.8 ± 1.1 1.8 ± 1.0 ns** 1.7 ± 0.8 2.0 ± 1.1 ns**
IL-4 2.0±0.7 2.0 ± 0.7 1.9 ± 0.7 ns** 1.9 ± 0.8 2.0 ± 0.7 ns** 1.9 ± 0.6 2.0 ± 0.8 ns**
IL-6 1.4±1.6 1.4 ± 1.8 1.1 ± 0.7 ns** 1.3 ± 0.8 1.4 ± 1.8 ns** 1.9 ± 2.2 1.0 ± 0.6 0.016*
0.017**
IL-8 4.5±5.6 4.3 ± 4.8 5.6 ± 9.4 ns** 2.7 ± 2.0 4.8 ± 6.0 ns** 4.6 ± 5.5 4.3 ± 5.8 ns**
IL-10 0.6±0.5 0.6 ± 0.5 0.5 ± 0.3 ns** 0.5 ± 0.3 0.6 ± 0.5 ns** 0.6 ± 0.3 0.6 ± 0.6 ns**
VEGF 35.3±31.8 37.3 ± 32.3 23.3 ± 26.6 ns** 33.9 ± 33.7 35.6 ± 31.7 ns** 40.7 ± 34.4 30.1 ± 28.7 ns**
IFN-γ 0.3±0.8 0.4 ± 0.9 0.2 ± 0.1 ns** 0.1 ± 0.1 0.4 ± 0.9 ns** 0.4 ± 1.0 0.3 ± 0.6 ns**
TNF-α 2.0 ± 1.8 2.1 ± 1.8 1.8 ± 1.3 ns** 1.5 ± 0.7 2.2 ± 1.9 ns** 2.0 ± 1.1 2.1 ± 2.2 ns**
IL-1A 0.3±0.2 0.3 ± 0.1 0.3 ± 0.2 ns** 0.2 ± 0.1 0.3 ± 0.2 ns** 0.3 ± 0.1 0.3 ± 0.2 ns**
IL-1B 1.6±1.0 1.6 ± 1.1 1.4 ± 0.9 ns** 1.2 ± 0.6 1.6 ± 1.1 ns** 1.6 ± 0.9 1.6 ± 1.2 ns**
MCP-1 83.4±73.9 85.4 ± 76.7 70.9 ± 55.5 ns** 130.2 ± 
102.8
73.9 ± 63.6 0.015*
0.050**
89.9 ± 75.6 77.4 ± 72.9 ns**
EGF 46.7±63.1 48.4 ± 64.5 36.6 ± 55.3 ns** 49.4 ± 58.4 46.1 ± 64.5 ns** 54.1 ± 70.0 39.9 ± 56.1 ns**
**ns (with nonparametric tests also): Mann–Whitney U test for continuous (beside parametric tests) and Kruskal–Wallis test for categorical variables; *within the group
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correlations: IL-2 with IL-4, IL-8, IL-10, IL-1A, IL-1B, 
and TNF-α (p = 0.000, p = 0.016, p = 0.000, p = 0.000, 
p = 0.000, and p = 0.000, respectively); IL-6 with IL-1A, 
TNF-α, VEGF, EGF, and MCP-1 (p = 0.047, p = 0.021, 
p = 0.000, p = 0.001, and p = 0.027, respectively); 
VEGF with EGF and MCP-1 (p = 0.000 and p = 0.014, 
respectively), EGF with MCP-1 (p = 0.005), etc., 
(Table 4).
After identifying inter-inflammatory biomarker 
correlations, we wanted to test possible associations 
with traditional CVD risk factors. Table 5 shows all 
statistically significant associations identified by 
univariate analysis. hsCRP shows significant association 
with female gender (p = 0,008 [OR 2,720 for f]) and IL-6 
(p = 0,005); IL-2 is associated with risk age (p = 0,006); 
IL-4 is reversely associated with total estimated 
EUROSCORE (%) and risk age (p = 0,011 and p = 0.054, 
respectively), and significantly associated with ApoB 
and Lp(a) (p = 0.006 and p = 0.036, respectively). IL-6 
is associated with family history for HLP, relative risk, 
and SBP (p = 0.046), as well as with hsCRP, CRP levels 
> 2 mg/L, and CRP as a category (OR 3.461 for the 
>3 mg/L category) (p = 0.005, p = 0.016, and p = 0.001, 
respectively). IL-8 is associated with Lp(a) (p = 0.044) 
and Acidum uricum (p = 0.008) and reversely associated 
with age (p = 0,005) and HTA (p = 0.032). IL-10 is also 
associated with family history for HLP, Chol, and LDL-C 
(p = 0.004, p = 0.038, and p = 0.003). IL-1A (same 
as Il-8) shows association with Lp(a) (p = 0.005) and 
Acidum uricum (p = 0.038), while IL-1B is associated 
with LDL-C (p = 0.040), and reversely associated with 
HbA1c (p = 0.050). IFN-γ shows association with family 
history for HLP (p = 0.050) and Lp(a) (p = 0.000), same 
as TNF-α (p = 0.001 and p = 0.003, respectively), 
which is also significantly associated with Chol, LDL-C, 
ApoB, Lp(a), and Acidum uricum (p = 0.001, p = 0.041, 
p = 0.004, p = 0.033, and p = 0.018, respectively), 
and reversely associated with age (p = 0.014). MCP-1 
shows a positive correlation with DM, glucose levels, 
and HbA1c (p = 0.015, p = 0.036, and p = 0.003, 
respectively). EGF shows a positive correlation with 
glucose levels (p = 0,013).
To test for independently associated variables 
with each of the studied inflammatory biomarkers, a 
multivariate analysis was performed using the linear 
regression model backward conditional (Table 6). hsCRP 
was reported to be positively correlated with HDL-C 
and IL-6 (p = 0.014). IL-6 was positively correlated with 
VEGF and EGF (p = 0.010 and p = 0.011, respectively). 
Both IL-1A and IL-1B were negatively correlated with 
HbA1c (p = 0.029 and p = 0.026, respectively). MCP-1 
was positively correlated with SBP (p = 0.013). VEGF 
was strongly positively correlated with EGF and vice 
versa (p = 0,000).
To identify independently associated variables 
with total estimated EUROSCORE risk, surpassing 
the traditional CVD risk factors that are being used 
to calculate the risk (age, gender, smoking status, 
total cholesterol, and SBP), a multivariate linear 
regression-backward analysis was performed where 
EUROSCORE risk was used as a single dependent 
variable, after exclusion of the previously mentioned 
EUROSCORE identifiers. The analysis revealed 5 
traditional risk factors and 7 inflammatory biomarkers 
Table 4: Correlations matrix between inflammatory cytokines
IL-4 IL-8 IL-10 IL-1A IL-1B IFNG TNFA VEGF EGF MCP-1
IL-2 Pearson correlation 0.482** 0.286* 0.676** 0.527** 0.443** 0.225 0.592**
Sig. (2-tailed) 0.000 0.016 0.000 0.000 0.000 0.059 0.000
IL-4 Pearson correlation 0.299* 0.409** 0.228 0.297* 0.317**
Sig. (2-tailed) 0.011 0.000 0.056 0.012 0.007
IL-6 Pearson correlation 0.237* 0.274* 0.460** 0.400** 0.262*
Sig. (2-tailed) 0.047 0.021 0.000 0.001 0.027
IL-8 Pearson correlation 0.606** 0.255* 0.274* 0.355** 0.425**
Sig. (2-tailed) 0.000 0.032 0.021 0.002 0.000
IL-10 Pearson correlation 0.461** 0.267* 0.747**
Sig. (2-tailed) 0.000 0.024 0.000
IL-1A Pearson correlation 0.452** 0.384** 0.553** 0.294*
Sig. (2-tailed) 0.000 0.001 0.000 0.013
IL-1B Pearson correlation 0.440**
Sig. (2-tailed) 0.000
IFNG Pearson correlation 0.422**
Sig. (2-tailed) 0.000
VEGF Pearson correlation 0.550** 0.291*
Sig. (2-tailed) 0.000 0.014
EGF Pearson correlation 0.329**
Sig. (2-tailed) 0.005
**ns (with nonparametric tests also): Mann–Whitney U test for continuous and Kruskal–Wallis test for categorical variables
Table 3: Gender distribution of inflammatory biomarker levels
Parameter Female 0/Male 1 N Mean ± SD Sig (parametric)
Sig* (Mann–Whitney U test)
CRP 0 (f) 41 41 4.2 ± 4.7 0.008
1 (m) 34 34 1.9 ±  1.5 0.002*
IL-2 0 39 1.9 ±  1.1 ns
1 32 1.8 ± 0.8
IL-4 0 39 2.0 ± 0.6 ns
1 32 1.9 ± 0.8
IL-6 0 39 1.9 ± 2.1 0.010 / 0.003*
1 32 0.9 ± 0.5
IL-8 0 39 3.6 ± 3.8 ns
1 32 5.5 ± 7.2
IL-10 0 39 0.6 ± 0.6 ns
1 32 0.6 ± 0.3
IL-1A 0 39 0.2 ± 0.1 ns
1 32 0.3 ± 0.2
IL-1B 0 39 1.4 ± 0.8 ns
1 32 1.8 ± 1.3
IFN-γ 0 39 0.4 ± 0.9 ns
1 32 0.3 ± 0.7
TNF-α 0 39 2.1 ± 1.9 ns
1 32 1.9 ± 1.6
VEGF 0 39 40.0 ± 35.5 ns
1 32 29.6 ± 26.0
EGF 0 39 471 ± 69.1 ns
1 32 46.3 ± 55.9
MCP-1 0 39 92.2 ± 89.9 ns
1 32 72.7 ± 47.1
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to be independently, significantly associated with total 
CVD risk (Table 7). 
Inflammatory biomarkers – discrimination 
ability
The inflammatory biomarker discrimination 
ability was tested against the patients’ SCORE risk 
profile using “receiver operating characteristic” (ROC) 
curves. The discriminatory function of the inflammatory 
biomarkers corresponds with the SCORE-risk profile 
severity; therefore, they do not have any statistically 
significant discrimination ability in patients at low-to-
moderate risk. IL-4, with its low values, was the only 
inflammatory biomarker to show a statistically significant 
discriminatory function in patients with high-to-very high 
risk (0.323; p = 0.021) (Figure 1). 
The inflammatory biomarker discrimination 
ability was tested against the patients’ hsCRP levels 
as well. IL-6, VEGF, and EGF were reported to have 
statistically significant discriminatory functions in 
patients with hsCRP levels < 1 mg/dl, with low values 
as determinants (0.284; p = 0.004; 0.359; p = 0.059; 
and 0.350; p=0.044, respectively) (Figure 2). 
IL-6 was shown to have a statistically significant 
discriminatory function in patients with hsCRP levels 
Table 5: Univariate analysis of inflammatory biomarkers and 
ASCVD risk identifiers
Inflammatory biomarker
hsCRP Beta Sig
Gender (f)
Risk age
HDL-C
IL-6
-0.303
0.229
0.236
0.332
0.008 (OR 2.720 for f)
0.048
0.042
0.005
IL-2
HTA (0)
Risk age (1)
LDL-C
IL-4
IL-8
IL-10
IL-1A
IL-1B
IFN-γ
TNF-α
-0.248
0.323
0.237
0.482
0.286
0.676
0.527
0.443
0.225
0.592
0.037
0.006
0.046
0.000
0.016
0.000
0.000
0.000
0.059
0.000
IL-4
Risk (categorical)
Risk age
ApoB
Lp(a)
IL-2
IL-8
IL-1A
IL-1B
IFN-γ
TNF-α
-0.301
-0.230
0.321
0.250
0.482
0.299
0.409
0.228
0.297
0.317
0.011
0.054
0.006
0.036
0.000
0.011
0.000
0.056
0.012
0.007
IL-6
Gender (f)
Family history (1)
Relative risk
SBP
hsCRP
CRP >2 mg/L
CRP categorical
IL-A1
TNF-α
MCP-1
VEGF
EGF
-0.304
0.238
0.238
0.237
0.332
0.285
0.385
0.237
0.274
0.262
0.460
0..400
0.010
0.046
0.046
0.046
0.005
0.016
0.001 (OR 3.461 for >3mg/L)
0.047
0.021
0.027
0.000
0.001
IL-8
Age
HTA
Lp(a)
Acidum uricum
IL-2 
IL-4
IL-1A
IL-1B
IFN-γ
TNF-α
VEGF
EGF
-0.333
-0.255
0.240
0.311
0.286
0.299
0.606
0.255
0.274
0.355
0.225
0.425
0.005
0.032
0.044
0.008
0.016
0.011
0.000
0.032
0.021
0.002
0.059
0.000
IL-10
Family history
HTA
Chol
LDL-C
IL-2
IL-1A
IL-1B
TNF-α
0.341
-0.225
0.247
0.350
0.676
0.461
0.267
0.747
0.004
0.059
0.038
0.003
0.000
0.000
0.024
0.000
IL-1A
Lp(a)
HbA1c
Acidum uricum
IL-2
IL-4
IL-6
IL-8
IL-10
IL-1B
INF-γ
TNF-α
VEGF
0.329
-0.229
0.247
0.527
0.409
0.237
0.606
0.461
0.452
0.384
0.553
0.294
0.005
0.055
0.038
0.000
0.000
0.047
0.000
0.000
0.000
0.001
0.000
0.013
IL-1B
LDL-C
HbA1c
IL-2
IL-4
IL-8
IL-10
IL-1A
TNF-α
0.244
-0.233
0.443
0.228
0.255
0.267
0.452
0.440
0.040
0.050
0.000
0.056
0.032
0.024
0.000
0.000
(Contd...)
Inflammatory biomarker
IFN-γ
Family history
Lp(a)
IL-2
IL-4
IL-8
IL-1A
TNF-α
0.234
0.672
0.225
0.297
0.274
0.384
0.422
0.050
0.000
0.059
0.012
0.021
0.001
0.000
TNF-α
Age
Family history
HTA
Chol
LDL-C
ApoB
Lp(a)
Acidum uricum
IL-2
IL-4
IL-6
IL-8
IL-10
IL-1A
IL-1B
-0.290
0.375
-0.230
0.243
0.336
0.253
0.351
0.280
0.592
0.317
0.274
0.355
0.747
0.553
0.440
0.014
0.001
0.054
0.041
0.004
0.033
0.003
0.018
0.000
0.007
0.021
0.002
0.000
0.000
0.000
MCP-1
DM
SBP
Gl
HbA1c
IL-6
VEGF
EGF
0.288
0.231
0.249
0.352
0.262
0.291
0.329
0.015
0.052
0.036
0.003
0.027
0.014
0.005
VEGF
IL-6
IL-8
IL-1A
MCP-1
EGF0
0.460
0.225
0.294
0.291
0.550
0.000
0.059
0.013
0.014
0.000
EGF
Gl
IL-6
IL-8
MCP-1
VEGF
0.292
0.400
0.425
0.329
0.550
0.013
0.001
0.000
0.005
0.000
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Table 6: Multivariate analysis of independently associated 
variables (Linear regression model)
Dependent variable Variables in the model Beta t Sig
hsCRP
R square .222; p=0.001
HDL-C
IL-6
0.272
0.285
2.518
2.524
0.014
0.014
IL-2
R square .650; p=0.000
RISK age
IL-4
IL-10
IL-1B
0.174
0.352
0.537
0.233
2.321
4.527
6.997
3.035
0.023
0.000
0.000
0.003
IL-4
R square 0.650; p=0.000
Risk categorical
TG
ApoA1
ApoB
IL-2
IL-10
IL-1A
-0.365
0.273
0.149
0.299
0.530
-0.391
0.388
-4.314
3.085
1.748
3.323
4.262
-3.353
3.714
0.000
0.003
0.085
0.001
0.000
0. 0.001
0.000
IL-6
R square 0.585; p=0.000
female 0/ male 1
SBP
hsCRP
TNF-α
VEGF
EGF
-0.164)
0.345
0.291
0.216
0.282
0.276
-1.781
3.932
3.218
2.455
2.664
2.628
0.080
0.000
0.002
0.017
0.010
0.011
IL-8
R square 292.180; p=0.000
Age
Acidum uricum
IL-1A
EGF
-0.222
0.185
0.468
0.268
-2.546
2.102
5.208
3.056
0.013
0.039
0.000
0.003
IL-10
R square 2.591; p=0.000
IL-2
IL-4
IL-1B
TNF-α
0.482
-0.163
-0.168
0.587
5.039
-2.061
-2.108
6.619
0.000
0.043
0.039
0.000
IL-1A
R square 0.169; p=0.000
Lp(a)
HbA1c
IL-2
IL-8
IL-10
VEGF
0.169
-0.176
0.286
0.404
0.190
0.149
2.085
-2.237
2.615
4.790
1.799
1.852
0.041
0.029
0.011
0.000
0.077
0.069
IL-1B
R square 6.662; p=0.000
HbA1c
IL-2
IL-10
TNFA
-0.233
0.463
-0.364
0.410
-2.281
3.313
-2.182
2.655
0.026
0.001
0.033
0.010
IFN-γ
R square 8.491; p=0.000
Lp(a)
IL-2
0.646
0.179
7.463
2.082
0.000
0.041
TNF-α
R square 28.315; p=0.000
Age
Lp(a)
Acidum uricum
IL-6
IL-10
IL-1B
-0.115
0.287
0.114
0.122
0.648
0.181
-1.743
4.465
1.799
1.904
9.882
2.790
0.086
0.000
0.077
0.061
0.000
0.007
MCP-1
R square 30469.901; p=0.000
SBP
HbA1c
VEGF
EGF
0.267
0.325
0.229
0.230
2.551
3.119
1.857
1.841
0.013
0.003
0.068
0.070
VEGF
R square 13133.260; p=0.000
IL-6
EGF
0.286
0.436
2.725
4.154
0.008
0.000
EGF
R square 29504.865; p=0.000
IL-6
IL-8
IL-1A
Gl
VEGF
0.169
0.371
-0.223)
0.304
0.477
1.741
3.429
-2.038)
3.500
4.841
0.086
0.001
0.046
0.001
0.000
> 3 mg/dl, with high values as determinants (0.776; 
p=0.000) (Figure 3). 
hsCRP and IL-6
Tables 8 and 9 show statistically significant 
correlations of hsCRP and IL-6. hsCRP is positively 
Table 8: hsCRP significant correlations
Control variable female 0/ male 1 RISK age HDL-C IL-6
hsCRP Correlation -0.303 0.229 0.236 0.332
Significance (2-tailed) 0.008 0.048 0.042 0.005
df 73 73 73 73
Table 7: Variables independently associated with EUROSCORE 
risk. after exclusion of identifiers of EUROSCORE (age. gender. 
smoking. total cholesterol. and SBP). with multivariate linear 
regression-backward. mean square of the model 66.565; sig 
0.000
EUROSCORE (%) Variables in the model Beta t Sig
(Constant)
LDL-C (mmol/L)
HDL-C (mmol/L)
TG (mmol/L)
ApoB (mg/dl)
HbA1c (%)
hsCRP (mg/dl)
IL-4
IL-6
IL-10
VEGF
IL-1A
EGF
0.439
-0.176
0.335
0.720
0.466
0.190
-0.498
0.475
-0.242
-0.240
0.491
-0.232
-4.637
3.314
-1.995
3.585
5.451
5.496
2.085
-4.903
4.520
-2.432
-2.197
4.278
-2.290
0.000
0.002
0.051
0.001
0.000
0.000
0.042
0.000
0.000
0.018
0.032
0.000
0.026
Test result variables Area Std. errora Sig.b Asymptotic 95% CI
Lower bound Upper bound
IL-2 0.513 0.078 0.867 0.360 0.665
IL-4 0.538 0.079 0.606 0.383 0.694
IL-6 0.284 0.066 0.004 0.155 0.413
IL-8 0.434 0.077 0.377 0.283 0.585
IL-10 0.482 0.077 0.808 0.330 0.633
IL-1A 0.416 0.078 0.260 0.264 0.568
IL-1B 0.481 0.082 0.799 0.321 0.641
IFN-γ 0.570 0.071 0.351 0.430 0.709
TNF-α 0.422 0.079 0.293 0.267 0.577
VEGF 0.359 0.069 0.059 0.224 0.494
EGF 0.350 0.072 0.044 0.210 0.490
MCP-1 0.386 0.075 0.126 0.240 0.532
Figure 2: ROC-curves  for  inflammatory biomarkers  in patients with 
hsCRP<1 mg/dL
Test result variable(s) Area Std. errora Asymptotic Sig.b Asymptotic 95% CI
Lower 
bound
Upper 
bound
hsCRP 0.610 0.072 0.150 0.470 0.751
IL-2 0.453 0.076 0.544 0.304 0.603
IL-4 0.323 0.068 0.021 0.189 0.456
IL-6 0.538 0.078 0.623 0.384 0.691
IL-8 0.438 0.076 0.421 0.289 0.587
IL-10 0.468 0.076 0.673 0.319 0.616
VEGF 0.516 0.079 0.838 0.361 0.670
IFN-γ 0.470 0.076 0.692 0.321 0.618
TNF-α 0.481 0.072 0.803 0.340 0.621
IL-1A 0.493 0.074 0.924 0.348 0.637
IL-1B 0.549 0.076 0.523 0.401 0.697
MCP-1 0.580 0.076 0.295 0.431 0.730
EGF 0.404 0.075 0.213 0.257 0.552
Figure 1: ROC-curves  for  inflammatory biomarkers  in patients with 
high and very high EUROSCORE risk
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correlated with female gender, risk age, HDL-C, and 
IL-6 (p = 0.008, p = 0.048, p = 0.042, and p = 0.005) 
(Table 8). IL-6 is positively correlated with relative 
risk, risk age, and hsCRP (p = 0.019, p = 0.023, and 
p = 0,000) (Table 9).
Table 9: IL-6 significant correlations (nonparametric 
correlations)
Control variable Relative risk Risk age hsCRP 
IL-6 Correlation 0.278 0.270 0.443*
Significance (2-tailed) 0.019 0.023 0.000
df 73 73 73
*With nonparametric tests also.
To determine any “cut-off” value of IL-6, we 
performed a stepwise discriminatory testing and 
we found that IL-6 levels > 1 pg/ml demonstrate a 
significant discriminatory function. Table 10 shows 
all statistically significant correlations of IL-6 levels > 
1 pg/ml and CVD risk factors identified by univariate 
binary logistic regression analysis. IL-6 levels above 
1 pg/ml are correlated with female gender, age > 55 
years, EUROSCORE (%) ≥ 3, risk age, SBP, hsCRP 
> 2 mg/L, and IL-2 (p = 0.025, p = 0.013, p = 0.025, 
p = 0.011, p = 0.026, p = 0.046, and p = 0.018, 
respectively).
To identify independently associated variables 
with IL-6 levels above 1 pg/ml, a multivariate linear 
regression-backward analysis was performed using IL-6 
> 1 pg/ml as a single dependent variable. The analysis 
revealed female gender, age above 55 years, HTA (or 
SBP > 140 mmHg), hsCRP levels above 2 mg/L, and 
IL-2 to be independently, significantly associated with 
IL-6 > 1 pg/ml (Table 11).
Table 11: Variables independently associated with IL-6 > 
1 pg/ml. with multivariate logistic regression model (backward 
conditional). Chi-square of the model 32.169; p=0.000; percent 
of correct prediction 78.9%
B Wald Sig. Exp(B) 95% C.I. for EXP(B)
Lower Upper
Gender (f) -1.528 4.960 0.026 0.217 0.057 0.833
Age > 55 1.595 6.091 0.014 4.928 1.389 17.492
SBP > 140 mmHg 1.757 6.433 0.011 5.797 1.491 22.539
hsCRP > 2 mg/L 1.064 2.826 0.093 2.897 0.838 10.014
IL-2 1.252 9.757 0.002 3.497 1.594 7.672
Constant -3.571 10.673 .001 0.028
Discussion
The aim of this study was to test for a possible 
correlation between the cardiovascular risk profile 
of healthy subjects at medium-to-high CVD risk and 
various inflammatory markers, and assess whether IL-6 
can serve as a better inflammatory marker than CRP in 
CVD risk prediction. To achieve our goals, we included 
75 adult ambulatory patients without an established 
CVD, obtaining the levels of various biochemical and 
inflammatory markers and establishing the subjects’ 
complete risk profile. Patients were analyzed by three 
indicators: HLP, DM, and a hsCRP value >2 mg/L. The 
previous was based on: 1. The well-established role 
of HLP as a CVD risk factor [18]; 2. The reciprocal 
relationship between DM and CVD; a hypothesis that the 
two diseases share common antecedents, supported 
by the recently discovered shared molecular drivers, 
pathways and gene subnetworks [19], [20], [21]; and 
3. hsCRP values above 2 mg/L are considered as an 
indicator of increased CVD risk [10], [11], [22]. 
Our study population showed a total estimated 
EUROSCORE (%) of 3,5, with a relative risk of 2,7, 
meaning a 3-fold increased CVD risk compared to an 
equivalent population with normal risk factor values. 
More than half of the study population (62,7%) had 
a risk age above their actual biological age. Testing 
for significant associations between the patients’ 
subgroups revealed two interesting correlations; 
DM was positively correlated with MCP-1 levels 
(130,2 ± 102,8 vs. 73,9 ± 63,6, p=0.050) and hsCRP 
levels > 2mg/L were positively correlated with IL-6 
levels (1.9 ± 2.2 vs. 1.0 ± 0.6, p = 0.017). Diabetic 
2518GG-carriers (a polymorphism in the gene that 
regulates MCP-1 expression) have been found to have 
elevated circulating MCP-1 levels and increased insulin 
Table 10: Univariate binary logistic regression analysis of IL-6 
> 1 pg/ml and CVD risk factors
IL-6 > 1 pg/ml
Variable Wald OR (95% CI) Sig
Gender (f)
Age >55y
DM
EUROSCORE ≥3
Risk age
SBP (mmHg)
hsCRP > 2 mg/L
IL-2
5.051
6.131
3.483
5.012
6.459
6.965
3.978
5.595
3.055 (1.154 – 8.088)
3.562 (1.303 – 9.739)
3.808 (.935 – 15.504)
3.087 (1.151 – 8.284)
3.030 (1.143 – 8.036)
2.654 (1.017 – 6.925)4
0.025
0.013
0.062
0.025
0.011
0.026
0.046
0.018
Test result variables Area Std. errora Asymptotic Sig.b Asymptotic 95% CI
Lower bound Upper bound
IL-2 0.451 0.072 0.514 0.310 0.593
IL-4 0.398 0.070 0.173 0.262 0.535
IL-6 0.776 0.061 0.000 0.656 0.897
IL-8 0.542 0.075 0.572 0.396 0.689
IL-10 0.564 0.075 0.391 0.418 0.710
IL-1A 0.514 0.071 0.847 0.375 0.654
IL-1B 0.505 0.070 0.945 0.367 0.643
IFN-γ 0.477 0.081 0.761 0.318 0.637
TNF-α 0.579 0.069 0.291 0.443 0.714
VEGF 0.511 0.075 0.881 0.364 0.658
EGF 0.557 0.073 0.448 0.413 0.700
MCP-1 0.547 0.074 0.526 0.402 0.693
Figure 3. ROC-curves  for  inflammatory biomarkers  in patients with 
hsCRP>3 mg/dL
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resistance [23]. The connection between hsCRP and 
IL-6 will be addressed later in the article.
Compared to males, females showed 
higher levels of hsCRP and IL-6 (4.2 ± 4.7 vs. 1.9 ± 
1.5 and 1.9 ± 2.1 vs. 0.9 ± 0.5, with both parametric 
and nonparametric tests (p = 0.008/p = 0.002 and 
p = 0.010/p=0.003, respectively). Gender and race have 
been shown to affect hsCRP levels, with higher hsCRP 
concentrations found in females [24]. Milan-Mattos et al. 
(2019) evaluated IL-6 and hsCRP levels in healthy men 
and women of different age groups. Women presented 
with stronger correlations, compared to men, for both 
IL-6 and hsCRP, and the 51–60 age group was the key 
point for the increase [25].
We used several statistical methods to 
identify correlations between the inflammatory markers 
and traditional risk factors, as well as amongst 
the inflammatory markers themselves. Numerous 
statistically significant correlations were detected 
(Table 4), adding to the principle of the “inflammatory 
cascade.” TNF-α is one of the most potent pro-
inflammatory cytokines appearing early in the 
inflammatory response, which despite its own actions 
on different signal transduction pathways, enhances the 
inflammatory response by stimulating IL-1A, IL-1B, IL-8, 
and MCP-1 synthesis in macrophages and endothelial 
cells [26]. IL-6 is another major cytokine that acts early 
in the inflammatory response, stimulating hepatic 
production of acute-phase proteins, including CRP [27]. 
IL-6 also acts by inducing VEGF and EGF synthesis in 
endothelial cells, both major regulators of angiogenesis 
and vasculogenesis [28]. EGF is thought to exert its 
angiogenic effects on vascular endothelial cells by 
stimulating the autocrine secretion of VEGF [29]. Plenty 
of evidence can be found in the scientific literature 
regarding associations between different inflammatory 
cytokines that can be used to explain the correlations 
obtained in our study.
Statistically significant associations of every 
studied inflammatory biomarker, obtained with both 
univariate and multivariate analysis, are shown 
in Tables 5 and 6. We will only present several 
correlations with subsequent scientific evidence. 
hsCRP was reported to be positively correlated with 
HDL-C and IL-6 (p=0,014). Given that lower HDL-C 
levels are considered a CVD risk factor, its proportional 
correlation with hsCRP, which is a pro-inflammatory 
marker, is unexpected. However, there are recent 
findings stating that HDL may become dysfunctional 
in some disease states, such as atherosclerosis. 
Activation of an acute phase response (characterized 
with increased hsCRP levels) leads to HDL changes, 
such as loss of apoA-I and paraoxonase (PON) and 
incorporation of acute-phase proteins, which in turn 
reduces the HDL anti-oxidant capacity. Accordingly, 
higher HDL-C concentrations are needed to counter-
balance the increased hsCRP levels [30], [31], [32]. 
Further studies are needed. IL-4 was negatively 
correlated with total estimated EUROSCORE (%) and 
risk age (p = 0.011 and p = 0.054, respectively), and 
positively correlated with ApoB and Lp(a) (p = 0.006 
and p = 0.036, respectively). IL-4 is a cytokine with 
varying pro/anti-inflammatory actions depending on 
the overall state of the subject [33]. In healthy subjects, 
IL-4 exerts anti-inflammatory actions by suppressing 
monocyte and macrophage pro-inflammatory cytokine 
production, explaining its negative correlation with 
total CVD risk [34]. However, recent in vitro and in vivo 
studies have provided evidence that IL-4 exerts pro-
inflammatory effects on the vascular endothelium 
in patients with disturbed lipid balance, such as 
increased levels of ApoB and Lp(a) [35]. IL-8, IL-1A, 
IFN-γ, and TNF-α all showed positive correlations with 
Lp(a) (p = 0.044, p = 0.005, p = 0.000, and p = 0.003, 
respectively). Lp(a) promotes differentiation of the 
pro-inflammatory, M1-type macrophages that secrete 
numerous pro-inflammatory cytokines, such as IL-1A 
and IL-1B, IL-6, IL-8, TNF-α, and IFN-γ, which is 
considered to be one of the mechanisms responsible 
for its proatherosclerotic potential [36]. IL-8, IL-1A, and 
TNF-α were all positively correlated with Acidum uricum 
(p = 0.008, p = 0.038, and p = 0.018, respectively). 
Recent studies have shown that high levels of Acidum 
uricum predict HTA and CV event development, 
possibly through inflammation. Tissue damage releases 
endogenous substances, including Acidum uricum, 
which signals danger and stimulates inflammation. 
The secreted Acidum uricum then enters the vascular 
smooth muscle cells stimulating CRP and MCP-1 
release. It also penetrates human mononuclear cells, 
where it stimulates IL-1, IL-8, and TNF-α production [37]. 
MCP-1 showed a positive correlation with DM, glucose 
levels, and HbA1c (p = 0.015, p = 0.036, and p = 0.003, 
respectively). Circulating MCP-1 levels have been found 
to be significantly increased in Type 2 diabetic patients, 
carriers of the MCP-1 G-2518 gene variant. High 
glucose levels stimulate endothelial cells to increase 
MCP-1 release, as well as increase basal expression of 
vascular cell adhesion molecule-1 (VCAM-1), leading to 
a synergistic enhancement of the monocyte-endothelial 
cell interaction [38].
A multivariate linear regression-backward 
analysis combining the traditional risk factors and 
inflammatory biomarkers (surpassing the CVD 
indicators used to calculate EUROSCORE risk) 
revealed 12 markers to be significantly, independently 
associated with CVD risk – LDL-C, TG, ApoB, HbA1c, 
hsCRP, IL-6, and IL-1A as markers of higher, and HDL-
C, IL-4, Il-10, VEGF, and EGF as markers of lower CVD 
risk (Table 7). 
We tested the inflammatory biomarker 
discrimination abilities using ROC curves, according 
to the previously discussed subjects’ subgroups. The 
discriminatory function of the inflammatory biomarkers 
corresponds with the SCORE-risk profile severity 
and hsCRP levels; they did not show any statistically 
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significant discrimination ability regarding the presence/
absence of DM. IL-4, with its low values, was the only 
inflammatory biomarker to show a statistically significant 
discriminatory function in patients at high-to-very high 
CVD risk (0.323; p = 0.021). Its anti-inflammatory 
potential was previously discussed. IL-6 was shown to 
have a statistically significant discriminatory function in 
patients with hsCRP levels > 3 mg/dl, with high values 
as determinants (0.776; p = 0.000). 
Every single correlation test, univariate, 
or multivariate analysis, we did show a statistically 
significant positive association between hsCRP and 
IL-6. Even ROC curves testing discriminatory function 
of different inflammatory markers identified IL-6 as a 
major, proportional determinant of hsCRP levels. The 
previous can be explained by the inflammatory pathway 
of hsCRP – hsCRP is the final downstream biomarker 
of a complex cascade which includes intermediate 
IL-6 and upstream IL-1 signaling pathways. IL-6 binds 
directly to the cellular membrane-bound IL-6 receptor, 
expressed on hepatocytes and several white blood 
cells, forming a signaling complex that leads to acute-
phase protein production, including hsCRP synthesis. 
On the other hand, part of the circulating IL-6 binds to 
the soluble portion of the IL-6 receptors, forming a binary 
complex, which has been shown to have independent 
pro-inflammatory activities, additional to the hsCRP 
synthesis induction [39]. 
Like hsCRP, IL-6 levels, measured in 
apparently healthy populations, also predict future 
vascular risk, an observation made in more than 25 
prospective epidemiologic cohorts worldwide. For each 
SD increase in log IL-6, there is a 25% increase in the 
risk of future vascular events (RR 1.25, 95%CI 1.19-
1.32). IL-6 levels have been shown to correlate with 
endothelial dysfunction, arterial stiffness, and extent of 
sub-clinical atherosclerosis [17].
Taking into consideration the previous, we 
wanted to test whether IL-6 can be used as a sole 
inflammatory marker instead of hsCRP. We chose 
a cut-off IL-6 value of 1 pg/ml – given the results 
obtained with our study and the source scientific data. 
A univariate analysis showed that IL-6 levels above 
1 pg/ml are significantly, positively correlated with 
female gender, age > 55 years, EUROSCORE (%) ≥ 3, 
risk age, SBP, hsCRP > 2 mg/L, and IL-2 (p = 0.025, 
p = 0.013, p = 0.025, p = 0.011, p = 0.026, p = 0.046, 
and p = 0.018, respectively). Except for total CVD 
risk and risk age, the same variables were identified 
as independently associated variables with IL-6 levels 
above 1 pg/ml, with a multivariate linear regression-
backward analysis. Our results were in accordance with 
current scientific reports [40], [41], [42], [43], [44]. 
Limitations of the study
Due to the small sample size, the number of 
subjects in each subgroup is not equal. We think that 
this is the main reason for omitting possible statistically 
significant associations that would appear with larger 
sample size and proportional subject distribution. 
Conclusion
In this cohort of healthy subjects, total CVD risk 
was strongly and independently associated with several 
circulating markers of inflammation. hsCRP appears to 
be in a strong reciprocal relationship with IL-6. IL-6 was 
significantly and independently correlated with several 
traditional risk factors, as well as with hsCRP and IL-2. 
Therefore, IL-6 may have a potential role as a mediator 
between cardiovascular risk factors and several 
biological mechanisms for CVD not only in diagnostic 
but also in therapeutic goals as well.
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Appendices
Appendix 1
Glycemic profile - Glucose concentration was determined by a hexokinase enzymatic method (NADPH 
production is measured spectrophotometrically at 340 nm using COBAS INTEGRA Glucose HK Gen. 3). HgA1c 
concentration was determined by a turbidimetric inhibition-based immunoassay (COBAS INTEGRA, Tina-quant 
Gen.2, Roche Diagnostics).
Lipoprotein profile – Cholesterol concentration was determined using a colorimetric enzymatic method (color 
intensity is measured spectrophotometrically at 512 nm using COBAS INTEGRA Cholesterol Gen.2 (CHOL2), Test 
CHOL2, Test ID 0-586). HDL-C concentration was determined by a homogenous colorimetric enzymatic method 
(Color intensity is measured spectrophotometrically at 583 nm using COBAS INTEGRA HDL-cholesterol plus 2nd 
generation (HDL-C); HDL-C test, ID 0-201). LDL-C was determined by a homogenous colorimetric enzymatic 
method (color intensity is measured spectrophotometrically at 583 nm using COBAS INTEGRA LDL-cholesterol 
plus 2nd generation (LDL-C); LDL-C Test, ID 0-301). Triglycerides were determined by a colorimetric enzymatic 
method (color intensity is measured spectrophotometrically at 512 nm using COBAS INTEGRA triglycerides 
(TRIGL); test TRIGL, test ID 0-010). ApoAI and ApoB were measured turbidimetrically at 340 nm, using anti-ApoAI 
and anti-ApoB antiserum (COBAS INTEGRA Tina-quant Apolipoprotein A-1ver.2 and COBAS INTEGRA Tina-
quant Apolipoprotein B ver.2, Roche). Lp(a) was determined turbidimetrically at 800/660 nm (COBAS INTEGRA 
Tina-quant® Lipoprotein (a) Gen. 2, Roche).
Inflammatory profile – Quantitative determination of IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, INF-
γ, MCP-1, EGF, and VEGF was done using a commercial Randox cytokine and growth factors array kit, based on 
a sandwich chemiluminescent immune test. The concentration of C-reactive protein was determined by a latex 
immunoturbidimetric method (COBAS INTEGRA Tina-quant® CRP (Latex) assay, Roche).
